hat das Anfang Mai'15, neben anderen Alternativen, vorhergesagt. War aber auch nicht so schwierig, bzw.bedurfte keiner Insiderinformationen. Man musste nur die Reichweite des Cashs betrachten um zu sehen, dass die Wirtschaftsprüfer Medigene bald Druck machen würden.
"Eingerechnet" waren diese "60Mio." aber damals noch nicht. (s.letzten Satz)
"We note that Medigene has approximately 12m new shares available within its authorised capital (as of 31 December 2014). At the current share price, just 1m shares would need to be sold (7%dilution) to meet the €10m funding requirement in 2016. We note that selling up to 6m shares (50% of the authorised capital) at the current stock price would raise >€60m and be potentially transformational in terms of providing sufficient funds to advance its DC vaccine and TCR
programmes to all-important Phase II valuation inflection points.
Our financial model, which does not include such fund-raising assumptions, is summarised in Exhibit 9." |
Thread abonnieren
